News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BEAT BioTherapeutics Corporation Closes $2.5 Million Seed Financing to Develop Its Gene Therapy Treatment for Heart Failure


4/16/2013 10:45:22 AM

SEATTLE--(BUSINESS WIRE)--BEATBio, a Seattle, Wash.-based biotechnology company focused on the development of a novel gene therapy to improve cardiac performance in the setting of heart failure, today announced the closing of a $2.5 million seed stage investment with funding provided by CET Capital Partners. Participating investors include the W Fund. The proceeds will be used to move BEATBio’s lead gene therapy product into clinical development.

Read at BioSpace.com

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES